Maze Therapeutics (MAZE) Non-Current Assets (2024 - 2026)
Maze Therapeutics (MAZE) posted Non-Current Assets of $39.9 million for Q1 2026, down 15.78% sequentially from $47.4 million in Q4 2025, and up 20.52% YoY from $33.1 million in Q1 2025.
Maze Therapeutics (MAZE) Non-Current Assets (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Non-Current Assets for 3 years, with the latest figure at $39.9 million in Q1 2026.
- Quarterly Non-Current Assets rose 20.52% year-over-year to $39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $150.5 million (changed N/A YoY) and the FY2025 annual result came in at $47.4 million, up 21.97% from the prior year.
- Non-Current Assets retreated to $39.9 million in Q1 2026 per MAZE's latest filing, from $47.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $47.4 million in Q4 2025 and troughed at $30.8 million in Q3 2025.
- A 3-year average of $37.1 million and a median of $36.0 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets grew 21.97% in 2025, then grew 20.52% in 2026.
- Over 3 years, Non-Current Assets stood at $38.9 million in 2024, then gained by 21.97% to $47.4 million in 2025, then declined by 15.78% to $39.9 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $39.9 million, $47.4 million, and $30.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 111.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.20 Mn |
| Mar 31, 2026 | 39.93 Mn |
| Dec 31, 2025 | 47.41 Mn |
| Sep 30, 2025 | 30.76 Mn |
| Jun 30, 2025 | 32.37 Mn |
| Mar 31, 2025 | 33.13 Mn |
| Dec 31, 2024 | 38.87 Mn |